The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers.
Research paper by
Leng L Han, Lixia L Diao, Shuangxing S Yu, Xiaoyan X Xu, Jie J Li, Rui R Zhang, Yang Y Yang, Henrica M J HM Werner, A Karina AK Eterovic, Yuan Y Yuan, Jun J Li, Nikitha N Nair, Rosalba R Minelli, Yiu Huen YH Tsang, Lydia W T LW Cheung, Kang Jin KJ Jeong, Jason J Roszik, Zhenlin Z Ju, Scott E SE Woodman, Yiling Y Lu, Kenneth L KL Scott, Jin Billy JB Li, Gordon B GB Mills, Han H Liang
Adenosine-to-inosine (A-to-I) RNA editing is a widespread post-transcriptional mechanism, but its genomic landscape and clinical relevance in cancer have not been investigated systematically. We characterized the global A-to-I RNA editing profiles of 6,236 patient samples of 17 cancer types from The Cancer Genome Atlas and revealed a striking diversity of altered RNA-editing patterns in tumors relative to normal tissues. We identified an appreciable number of clinically relevant editing events, many of which are in noncoding regions. We experimentally demonstrated the effects of several cross-tumor nonsynonymous RNA editing events on cell viability and provide the evidence that RNA editing could selectively affect drug sensitivity. These results highlight RNA editing as an exciting theme for investigating cancer mechanisms, biomarkers, and treatments.